Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1991 1
1992 32
1993 135
1994 167
1995 146
1996 169
1997 214
1998 189
1999 251
2000 241
2001 267
2002 279
2003 334
2004 332
2005 427
2006 446
2007 566
2008 628
2009 713
2010 819
2011 978
2012 1100
2013 1199
2014 1388
2015 1552
2016 1699
2017 1806
2018 1828
2019 1806
2020 1722
2021 1729
2022 1367
2023 1265
2024 1348
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,583 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial.
Prabhash K, Deshmukh C, Malhotra H, Sharma A, Jain M, Dhamne N, Nagarakar R, Ganesan P, Mahobia VK, Das CK, Kumar R, Shivanna PS, Avaronnan MP, Chaithanya PK, Chaudhary V, Singh K, Aagre S, Ravishankar B, Mehta D, Shilpa K, Maniar V, Chatterjee K, Majumdar SD, Dana R, Noronha V, Menon N, Sharma A, Pawar R, Shahavi V, Yadav R, Aiwale A. Prabhash K, et al. JCO Glob Oncol. 2024 Nov;10:e2400059. doi: 10.1200/GO.24.00059. Epub 2024 Nov 14. JCO Glob Oncol. 2024. PMID: 39541562 Clinical Trial.
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, Díaz-Manera J, Dimachkie MM, Kushlaf H, Mozaffar T, Roberts M, Schoser B, Hummel N, Kopiec A, Holdbrook F, Shohet S, Toscano A; PROPEL Study Group. Kishnani PS, et al. J Patient Rep Outcomes. 2024 Nov 13;8(1):132. doi: 10.1186/s41687-024-00805-w. J Patient Rep Outcomes. 2024. PMID: 39535661 Free PMC article. Clinical Trial.
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.
Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A. Baraliakos X, et al. Arthritis Res Ther. 2024 Nov 12;26(1):197. doi: 10.1186/s13075-024-03412-8. Arthritis Res Ther. 2024. PMID: 39533349 Free PMC article. Clinical Trial.
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.
Duan X, Li H, Kuang D, Chen P, Zhang M, Li T, Jiao D, Li Y, He X, Xing C, Wang H, Liu Y, Xie L, Zhang S, Zhang Q, Zhu P, Chang Y, Xie J, Ren J, Han X. Duan X, et al. Signal Transduct Target Ther. 2024 Nov 13;9(1):304. doi: 10.1038/s41392-024-02012-x. Signal Transduct Target Ther. 2024. PMID: 39532849 Free PMC article. Clinical Trial.
[Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase Ⅲ multicenter, randomized controlled trial].
Liu ZH, Jin QL, Zhang YX, Gong GZ, Wu GC, Yao LF, Wen XF, Gao ZL, Huang Y, Yang DK, Chen EQ, Mao Q, Lin SD, Shang J, Gong HY, Zhong LH, Yin HF, Wang FM, Hu P, Zhang XQ, Gao QJ, Xia P, Li C, Niu JQ, Hou JL; TMF Study Group. Liu ZH, et al. Zhonghua Gan Zang Bing Za Zhi. 2024 Oct 20;32(10):893-903. doi: 10.3760/cma.j.cn501113-20240807-00366. Zhonghua Gan Zang Bing Za Zhi. 2024. PMID: 39528324 Clinical Trial. Chinese.
[Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study].
Liu ZH, Jin QL, Zhang YX, Gong GZ, Wu GC, Yao LF, Wen XF, Gao ZL, Huang Y, Yang DK, Chen EQ, Mao Q, Lin SD, Shang J, Gong HY, Zhong LH, Yin HF, Wang FM, Hu P, Zhang XQ, Gao QJ, Jin CN, Li C, Niu JQ, Hou JL; TMF Study Group. Liu ZH, et al. Zhonghua Gan Zang Bing Za Zhi. 2024 Oct 20;32(10):883-892. doi: 10.3760/cma.j.cn501113-20240807-00365. Zhonghua Gan Zang Bing Za Zhi. 2024. PMID: 39528323 Clinical Trial. Chinese.
23,583 results
You have reached the last available page of results. Please see the User Guide for more information.